Goutham Sunny Highlighted PANOVA-3 Phase III Trial on TTFields Plus Chemotherapy in Locally Advanced Pancreatic Cancer

Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, shared a post on X։

“PANOVA-3 Phase III Breakthrough

In unresectable locally advanced pancreatic cancer (LA-PAC), adding Tumor Treating Fields (TTFields) to gemcitabine + nab-paclitaxel offers meaningful clinical gains.

Key Results:
– OS ↑: 16.2 vs 14.2 mo (HR 0.82, P=.039)
– Pain-free survival ↑: 15.2 vs 9.1 mo (P=.027)
– Distant PFS ↑: 13.9 vs 11.5 mo (P=.022)
– No gain in ORR, PFS, or local control

Side Effects:
– Device-related skin AEs in 76.3% (mostly mild/moderate)
– Grade 3 skin AEs in 7.7%
– No added systemic toxicity

Why It Matters:
– First positive phase III trial in LA-PAC in years
– Non-invasive TTFields improve survival endpoints
–  Requires patient adherence to device use
– Suggests new non-chemotherapy mechanism to enhance outcomes

TTFields + chemo = new frontier in pancreatic cancer care.”

Title: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Journal: JCO

Authors: Hani M. Babiker, Vincent Picozzi, Sreenivasa R. Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao Chunyi, Lucjan Wyrwicz, Erika Hitre, Arsen Osipov, Christelle de la Fouchardiere, Inmaculada Ales, Tomislav Dragovich, Woojin Lee, Kynan Feeney, Philip Philip, Makoto Ueno, Eric Van Cutsem, Thomas Seufferlein, Teresa Macarulla

Read the full article.

More posts featuring Goutham Sunny on OncoDaily.